Evaluating a Decision Aid for Melanoma Patients Receiving Treatment
Shared Decision Making in Melanoma Patients Receiving Adjuvant Therapy: Development of a Decision Aid Tool
Odense University Hospital · NCT06294379
This study tests a new tool called 'The Decision Helper' to see if it helps melanoma patients feel more involved in their treatment choices and reduces feelings of regret compared to those who don’t use it.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 150 (estimated) |
| Ages | 18 Years to 100 Years |
| Sex | All |
| Sponsor | Odense University Hospital (other) |
| Drugs / interventions | immunotherapy, Ipilimumab, Nivolumab, Pembrolizumab |
| Locations | 1 site (Odense C) |
| Trial ID | NCT06294379 on ClinicalTrials.gov |
What this trial studies
This study focuses on developing and assessing a Patient Decision Aid called 'The Decision Helper' for melanoma patients who are eligible for adjuvant therapy. It aims to determine the tool's acceptability among patients and clinicians, as well as its feasibility in clinical practice. Additionally, the study will compare levels of decisional regret between patients who use the Decision Helper and those who do not. The goal is to enhance patient involvement in treatment decisions and improve overall satisfaction with care.
Who should consider this trial
Good fit: Ideal candidates for this study are Danish-speaking patients diagnosed with stage 3 malignant melanoma who are eligible for adjuvant immunotherapy.
Not a fit: Patients with metastatic disease or those experiencing mental impairment may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could empower melanoma patients to make more informed decisions about their treatment options, potentially leading to better outcomes and reduced decisional regret.
How similar studies have performed: Other studies have shown success with similar decision aids in various cancer treatments, indicating a promising approach to enhancing patient decision-making.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Danish speaking * Diagnosed with stage 3 malignant melanoma * Eligible for adjuvant immunotherapy Exclusion Criteria: * Metastatic disease * Mental impairment
Where this trial is running
Odense C
- Odense University Hospital — Odense C, Denmark (RECRUITING)
Study contacts
- Study coordinator: Lærke K Tolstrup, PhD
- Email: laerke.tolstrup@rsyd.dk
- Phone: 40295129
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Malignant Melanoma